Study enrollment

Follow-up

 

 

 

 

Predicted phenotypic resistance

 

 

 

 

Predicted phenotypic resistance

Patient VL
(ART used)*
NNRTI
mutations
NRTI
mutations
NNRTI NRTI Months
after enrollment
VL
(ART used)*
NNRTI
mutations
NRTI
mutations
NNRTI NRTI
1 3,010 (1b) K101E+
V108I+
Y181C
D67N+
K70R+
M184V+
K219E
H: NVP
I: EFV; ETR
H: 3TC
I: AZT
L: d4T; ABC
PL: ddI
S: TDF
7 3,680 (1b) K101E+
Y181C
D67N+
K70R+
M184V+
K219E
H: NVP
I: EFV
   ETR
H: 3TC
I: AZT
L: d4T; ABC
PL: ddI
S: TDF
3 4,310 (1a) K101E+
V106M+
G190A
D67N+
M184V
H: EFV; NVP
I: ETR
H: 3TC
L: ABC
PL: ddI
S: d4T; AZT
    TDF
11 3,790 (1a) K101E+
V106M+
G190A
D67N+
K70R+
M184V+
K219Q
H: EFV; NVP
I: ETR
H: 3TC
I: AZT
L: d4T; ABC
PL: ddI
S: TDF
5 1,850 (1a) K103N+
V108I
A62V+
V75I+
M184V
H: EFV; NVP
S: ETR
H: 3TC
L: ddI; ABC
S: d4T; AZT
    TDF
6 6,150 (1a) K103N+
V108I
A62V+
V75I+
M184V
H: EFV; NVP
PL: ETR
H: 3TC
L: ddI; ABC
S: d4T; TDF
     AZT
6 773 (1a) V106M+
G190A+
A98G
M41L D67N+
K70R+
M184V
H: EFV; NVP
L: ETR
H: 3TC
I: d4T, ABC
    AZT
L: TDF
    ddI
9 4,530 (1a) A98G+
V106M+
G190A
D67N+
K70R+
M184V+
K219Q
H: EFV; NVP
L: ETR
H: 3TC
I: AZT
L: d4T
    ABC
PL: ddI
S: TDF
7 2,530 (1a) V106M+
Y188LH
D67N+
M184V+
K219E
H: EFV; NVP
L: ETR
H: 3TC
L: d4T; ABC
    AZT
PL: ddI
S: TDF
12 25,000 (1a) V90I+
V106M+ Y188L
M184V H: EFV; NVP
L: ETR
H: 3TC
PL: ABC
S: d4T; TDF
     ddI; AZT
12 49,900 (1a) K103N+
Y181C+
P225H
M184I H: EFV; NVP
I: ETR
H: 3TC
PL: ABC
S: d4T; TDF
    AZT
6 8,540 (1a) V90I+
K103N+
Y181C+
P225H
M184V H: EFV; NVP
I: ETR
H: 3TC
PL: ABC
S: d4T; TDF
    AZT; ddI
15 18,300 (1a) K101E+
Y188L
M184I H: EFV; NVP
L: ETR
H: 3TC
PL: ABC
S: d4T; TDF
    ddI; AZT
9 3,710 (1a) K101E+ Y188L M184V H: EFV; NVP
L: ETR
H: 3TC
PL: ABC
S: d4T; TDF
     ddI; AZT

18

407 (1a)

K103N+
P225H

M184V

H: EFV; NVP
L: ETR

H: 3TC
PL: ABC
S: d4T; TDF
    DDI; AZT

10

937 (1b)

K103N

M184V

H: EFV, NVP
S: ETR

H: 3TC
PL: ABC
S: d4T; TDF
     ddI; AZT

20

1,330 (1a)

K103N+
V108I

M184V

H: EFV; NVP
S: ETR

H: 3TC
PL: ABC
S: d4T; DDI
    TDF; AZT

10

3,010 (1a)

K103N+
V108I

M184V

H: EFV; NVP
S: ETR

H: 3TC
PL: ABC
S: d4T; TDF
    ddI; AZT

23

955 (1b)

V106M

A62V+
M184V

H: EFV; NVP
PL: ETR

H: 3TC
PL: ABC
S: d4T; TDF
    DDI; AZT

11

2,540 (1b)

V106M+ E138A

A62V+
M184V

H: EFV; NVP
L: ETR

H: 3TC
PL: ABC
S: d4T; TDF
     ddI; AZT

30

1,130 (1a)

K103N

---

H: EFV; NVP
S: ETR

S: all drugs

9

15,700 (1a)

K103N

V75I

H: EFV; NVP
S: ETR

PL: d4T; ddI
S: 3TC; TDF
     ABC; AZT

35

83,000 (1a)

Wild type

Wild type

S: all drugs

S: all drugs

9

2,670 (1a)

V106M

K70R+
M184V

H: EFV; NVP
PL: ETR

H: 3TC
PL: ABC; AZT
S: d4T; TDF;
    ddI

40

4 660

Not amplifiable

Not amplifiable

---

---

9

31,300

K103N+
P225H

V75I+
M184V

H: EFV; NVP
L: ETR

H: 3TC
L: ABC; DDI
S: d4T; AZT;
    TDF

NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI; VL, virus load (copies/mL); ART, antiretroviral therapy; EFV, Efavirenz; NVP, Nevirapine; ETR, Etravirine; 3TC, Lamivudine; d4T, Stavudine; TDF, Tenofovir; ABC, Abacavir; AZT, Zidovudine; DDI, Didanosine; S, Susceptible; PL, potentially low-level of resistance; L, low-level resistance; I, intermediate level of resistance; H, High level of resistance; Line 1a, EFV + 3TC + d4T; Line 1b, NVP + 3TC + d4T Underlined mutations = lost mutations; Bolded mutations=gained mutations and Italic mutations=Minor mutations, for Etravirine, according to the IAS USA-2009 list.
Background colors for predicted phenotypic resistance were: White if susceptible or potentially-low; Light gray if low or intermediate and dark gray if highly resistant.
Table 4a: Genotypic and predicted phenotypic drug resistance among patients with persistent virologic failure at follow-up